Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.50 |
| ▸ | CHRNG | P07510 | 4/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.50 |
| ▸ | CHRND | Q07001 | 4/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28360223 | 0.84 | SLC6A2 (0.67) | ALDH1A1CYP3A4TSHRCYP2C19CHRNB2 | |
| SCHEMBL11037118 | 0.84 | SLC6A2 (0.67) | ALDH1A1CYP3A4TSHRCYP2C19CHRNB2 | |
| SCHEMBL1714913 | 0.83 | SLC6A2 (0.50) | ALDH1A1CYP3A4TSHRCYP2C19CHRNB2 | |
| SCHEMBL1072701 | 0.83 | SLC6A2 (0.69) | ALDH1A1TSHRCYP2C19CHRNB2SLC6A2 | |
| Hydrochloric Acid SCHEMBL28057449 | 0.83 | SLC6A2 (0.65) | ALDH1A1TSHRCHRNB2SLC6A2CHRNB4 | |
| Hydrochloric Acid SCHEMBL22614730 | 0.83 | SLC6A2 (0.65) | ALDH1A1TSHRCHRNB2SLC6A2CHRNB4 | |
| SCHEMBL4874415 | 0.82 | CES2 (0.50) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C19 | |
| SCHEMBL16226061 | 0.82 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL6706135 | 0.82 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL7264542 | 0.82 | CYP2D6 (1.00) | CYP2D6MC4RALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332495-B2 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | NHWA PHARMA. CORPORATION (CN) | 2008-02-19 | — | — | US | claimed |
| US-20060148811-A1 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2006-07-06 | — | — | US | claimed |
| US-7332495-B2 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | NHWA PHARMA. CORPORATION (CN) | 2008-02-19 | — | — | US | disclosed |
| US-20060148811-A1 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148811-A1 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | AAK1, KCNJ1, KHK | CYP2D6 326/4885MC4R 2143/4885ALDH1A1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.